1274P Performance status (PS) and end-of-life (EOL) care in patients (pts) with metastatic prostate cancer (mPC) treated with androgen receptor targeted (ART) therapy

G Mellgard,Z Chakrani,S Mccroskery,N Saffran,N Taylor,B Liaw,M.D Galsky,W Oh,C-K Tsao,V Patel

doi:10.1016/j.annonc.2022.07.1407

1274P Performance status (PS) and end-of-life (EOL) care in patients (pts) with metastatic prostate cancer (mPC) treated with androgen receptor targeted (ART) therapy

G Mellgard, Z Chakrani + Show 8 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1407

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital

#Androgen Receptor Targeted #Metastatic Prostate Cancer + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1274P Performance status (PS) and end-of-life (EOL) care in patients (pts) with metastatic prostate cancer (mPC) treated with androgen receptor targeted (ART) therapy

Full Text